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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effectiveness of electrical stimulation with non-implanted devices, alone or in combination with other treatment, in the
management of stress urinary incontinence or stress-predominant mixed urinary incontinence in women.
B A C K G R O U N D
Description of the condition
Urinary incontinence (UI) affects 25% to 45% of women world-
wide (ICI 2013). UI presents in the following forms:
• Stress urinary incontinence (SUI): involuntary loss of urine
through physical exertion or effort, coughing or sneezing
• Urgency urinary incontinence (UUI): involuntary loss of
urine associated with a sudden and compelling desire (urgency)
to urinate that is difficult to delay
• Mixed urinary incontinence (MUI): involuntary loss or
urine associated with both stress and urgency
Symptomatic diagnosis of SUI is typically based on whether urine
leakage occurs with physical exertion or effort, as reported by
women themselves.
In addition, urodynamically proven stress incontinence (USI) is
diagnosed when urine leakage is seen by an observer on stress
such as coughing during urodynamic examination, in the absence
of a detrusor contraction (ICI 2013). Symptomative diagnosis of
MUI is based on self-report of urine leakage through both physical
exertion and urgency.
This review will include women with SUI, USI and stress-pre-
dominant MUI.
Several mechanisms are thought to contribute to stress urinary
incontinence:
• suboptimal pelvic floor muscle strength
• hypermobility or significant displacement of the urethra
and bladder neck during exertion
• intrinsic urethral sphincter deficiency (ICI 2013).
In women, these mechanisms may coexist (Kursh 1994) but few
clinical trials have distinguished between these underlying causes.
We will consider women whose incontinence may be due to any
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of these mechanisms together in this review.
Prevalence estimates of SUI range from 3% to 25% of adult
women, with older women more likely to be affected (ICI 2013).
Quality of life and sexual function are often substantially impaired
by SUI (Oh 2008). The ability to carry out daily activities can
be severely impacted by SUI, resulting in debilitating embarrass-
ment, social isolation and considerably decreased health-related
quality of life (Bartoli 2010). Women with SUI may be less likely
to participate in physical activity, which in turn has a detrimental
impact on overall health because inactivity is a risk factor for many
diseases (Bø 2004). Other evidence has shown that up to 50%
of women with UI will avoid intimacy with their partners (Roos
2014).
Furthermore, SUI is associated with a considerable economic bur-
den for women and for healthcare providers. For instance, routine
care, such as pads, can cost several hundreds of pounds a year for
each woman affected, while conservative treatment and surgery
each cost several thousand pounds for each woman (ICI 2013).
Description of the intervention
In Europe and the USA, conservative interventions such as pelvic
floor muscle training (PFMT), with or without biofeedback, are
recommended as first-line treatment for SUI (EAU 2015; NICE
2013; Qaseem 2014); however, many women may find it difficult
to adhere to these methods in the long term (Bø 2005; Dumoulin
2014).
Surgery is usually suggested as a second-line option where conser-
vative treatment has not improved a woman’s symptoms or she is
unwilling or unable to continue the treatment. Synthetic mid-ure-
thral tape, open or laparoscopic colposuspension and autologous
rectus fascia sling procedures are recommended by the National
Institute forHealth and Care Excellence (NICE), although the use
of surgery with tapes in the management of UI remains contro-
versial in terms of safety and adverse effects (Scottish Government
2015). The effectiveness of surgical management for SUI has been
investigated by several Cochrane Reviews (Dean 2006; Lapitan
2012; Nambiar 2014; Rehman 2011). Other older surgical proce-
dures, such as anterior repair or bladder neck needle suspension,
have generally been superseded due to lower effectiveness.
Other less invasive second-line treatment options available in some
countries include bulking agents, where a substance is injected
into the urethral wall to increase its size and allow it to remain
closed, or pharmacological therapy, typically with duloxetine. The
disadvantages of these treatments are that they are likely to be less
effective than surgery, and, in the case of drug therapy, long-term
adherence is usually necessary, and is associated with unpleasant
side effects (Alhasso 2005; Mariappan 2005). Bulking agents can
cause discomfort or bleeding when urinating and their effective-
ness decreases over time, requiring retreatment. Other available
treatments for SUI include artificial urinary sphincters, and com-
plementary therapies such as acupuncture.
It has been suggested that electrical stimulation (ES) could be used
as a first-line treatment instead of PFMT inwomenwho are unable
to contract their pelvic floor muscles voluntarily, or if PFMT alone
is not sufficiently effective. It may also be beneficial to combine
ES with the use of vaginal cones and drug therapy.
How the intervention might work
When a nerve is stimulated, signals travel both toward the periph-
ery and toward the central nervous system. Electrical stimulation
may elicit responses to these signals, which may come from the
central nervous system or the tissues innervated by the nerve, or
the central nervous system may be modified to reinterpret some
signals (Chancellor 2002; Fall 1994).
With respect to lower urinary tract dysfunctions, electrical stim-
ulation is applied particularly to the pelvic floor muscles, bladder
and sacral nerve roots. In the context of SUI, the aim of ES is to
improve pelvic floor muscle strength so that the pelvic floor mus-
cles can be recruited when needed to occlude the urethra (such
as before a cough) and to increase muscle bulk, which may help
reduce urine loss by coapting the urethral walls. Direct ES of the
pelvic floor is intended to stimulate motor-efferent fibres of the
pudendal nerve, which may elicit a direct contraction of the pelvic
floor muscles or the striated peri-urethral musculature, support-
ing the intrinsic part of the urethral sphincter-closing mechanism
((Fall 1991; Scheepens 2003). As such, ES might contribute to the
compensation of a weak intrinsic sphincter, but it is questionable
whether or not ES in such cases would be the first-choice treat-
ment option or would have any additional value to pelvic floor
muscle training (Ayeleke 2015).
It has been suggested that ES restores continence in women with
SUI by:
• strengthening the structural support of the urethra and the
bladder neck (Plevnik 1991);
• securing the resting and active closure of the proximal
urethra (Erlandson 1977);
• strengthening the pelvic floor muscles (Sand 1995);
• inhibiting reflex bladder contractions (Berghmans 2002;
Fall 1994);
• modifying the vascularity of the urethral and bladder neck
tissues (Fall 1991; Fall 1994; Plevnik 1991).
In the context of conservative or non-surgical, non-medical ther-
apy, ES can be applied using surface electrodes in the form of tran-
scutaneous or percutaneous ES. Transcutaneous ES is adminis-
tered via suprapubic or vulval surface electrodes, or vaginal/anorec-
tal plug electrodes; while percutaneous ES uses needle electrodes
in conjunction with a surface electrode placed close to the needle
to act as a reference electrode, e.g. posterior tibial nerve stimula-
tion, percutaneous nerve evaluation.
The frequency, dosage and duration of treatment with ES varies
considerably. Although success has been claimed for awide range of
2Electrical stimulation with non-implanted devices for stress urinary incontinence in women (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
parameters, the optimal set of parameters for each type of urinary
incontinence has not been determined. Clinical consensus from
the International Consultation on Incontinence (ICI) underlines
this uncertainty:
“EStim is provided by clinic-based mains powered machines or
portable battery powered stimulators with a seemingly infinite
combination of current types, waveforms, frequencies, intensities,
electrode types and placements. Without a clear biological ratio-
nale it is difficult to make choices about different ways of deliver-
ing EStim. Additional confusion is created by the relatively rapid
developments in the area of EStim, and a wide variety of stimula-
tion devices and protocols have been developed even for the same
condition” (ICI 2013).
Evidence from a systematic review has suggested that, in men,
ES with non-implanted devices is more effective than sham treat-
ment for urinary incontinence and that ES enhances the effective-
ness of pelvic floor muscle training in the short term (Berghmans
2013). Other evidence suggests that ES is more effective than
sham, placebo or no active intervention in the treatment of over-
active bladder and urgency urinary incontinence (Stewart 2016).
It is not yet clear whether ES has similar effects in women with
SUI.
Why it is important to do this review
ES has shown promise in the treatment of UUI, but the evidence
base for its use in treating SUI is inconclusive (Schreiner 2013).
Given the adherence issues with conservative treatment, the side
effects of drug therapy and the safety concerns regarding some
kinds of surgical intervention, it is important to investigate alter-
native options for women with SUI.
Many randomised controlled trials (RCTs) have been undertaken
investigating ES for SUI, compared to a variety of conservative
interventions for SUI such as pelvic floor muscle exercises, drug
therapy, vaginal cones, sham ES and no active treatment. Some
trials have found no evidence of a difference in treatment effect,
while others have found ES to be more effective than a compara-
tor intervention. Given the heterogeneity of ES treatments, it is
important to attempt to synthesise the available evidence relat-
ing to the diverse ES devices and protocols. Some of the earlier
evidence relating to ES for SUI in women has been synthesised
in previous publications (ICI 2013; Imamura 2010), but with a
growing number of trials addressing this question an up-to-date
and comprehensive systematic review is needed to obtain the best
possible estimate of the effectiveness of ES.
O B J E C T I V E S
To assess the effectiveness of electrical stimulation with non-im-
planted devices, alone or in combination with other treatment, in
the management of stress urinary incontinence or stress-predom-
inant mixed urinary incontinence in women.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Parallel or cross-over RCTs, quasi-RCTs (RCTs inwhich allocation
to treatment is by methods such as alternate medical records, date
of birth, or other predictable methods) and cluster-randomised
trials will be eligible for inclusion.
To critically appraise and summarise current evidence on the cost
effectiveness of ES we will also include relevant health economics
studies conducted alongside effectiveness studies that meet the
eligibility criteria for the effectiveness component of the review.
This includes:
• full economic evaluation studies of ES compared to other
treatments (i.e. cost-effectiveness analyses, cost-utility analyses,
cost-benefit analyses)
• partial economic evaluations of ES (i.e. cost analyses, cost-
description studies, cost-outcome descriptions)
• RCTs reporting more limited information, such as
estimates of resource use or costs associated with ES
Types of participants
Eligible studies will include adult women (18 years or older, or ac-
cording to study authors’ definitions of adult) with SUI or stress-
predominant MUI on the basis of symptoms, signs or urody-
namic diagnosis. The trialists will define the criteria used to clas-
sify women with SUI or stress-predominant MUI.
We will exclude studies of women with urgency-predominant
MUI,UUI only, or incontinence associatedwith a neurologic con-
dition or frailty. We will also exclude studies in men and women
where data are not reported separately by sex. We will exclude
studies including only men or children. We will include trials of
participants with MUI, UUI and SUI only if the data for women
with SUI are presented separately.We will include trials in women
with MUI if the condition is SUI-predominant.
Types of interventions
Eligible interventions will include any method of delivering elec-
trical stimulation with non-implanted devices.
We will exclude trials of magnetic stimulation and electro-
acupuncture.
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Eligible comparators will be no active treatment, placebo or sham
treatment, or any intervention intended to decrease SUI, includ-
ing conservative treatment (including complementary therapies,
pelvic floormuscle training (PFMT) and vaginal cones), drug ther-
apy and surgery. We will also include studies comparing different
ES methods. There will be no restrictions by type of device, stim-
ulation parameters (such as continuous, interrupted, duration of
stimulation), duration of treatment, route of administration (vagi-
nal, rectal, skin, pretibial area, etc.), or other similar factors. We
will exclude trials of different combinations of treatments if it is
not possible to identify the effect of the ES intervention (e.g. ES
plus another treatment versus other combined treatments).
We will make the following comparisons:
1. ES versus no active treatment
2. ES versus placebo or sham treatment
3. ES versus other conservative treatment (e.g. bladder
training, PFMT, biofeedback, magnetic stimulation)
4. ES versus drugs (e.g. duloxetine)
5. ES versus surgery or injection of bulking agents
6. ES plus another treatment versus the other treatment alone
7. One type of ES versus another
We will not include studies where the comparator interventions,
alone or as a supplement toES, are different in the intervention and
control arms (i.e. ES plus another treatment A versus a different
other treatment B, with or without ES).
Types of outcome measures
We will extract outcome data reported at the end of treatment
and at the end of the longest available follow-up period. We will
consider the following outcomes:
Primary outcomes
• Cure: number of women with self-reported continence
• Improvement: number of women with self-reported
improvement in SUI (cured or improved)
• Incontinence-specific quality-of-life (QoL) measures
(however defined by authors or by any validated measurement
scales such as International Consultation on Incontinence
Questionnaire (www.iciq.net))
Secondary outcomes
1. Satisfaction with treatment
2. Need for further treatment
3. QoL measures of general health status, e.g. SF-36
4. Quantification of symptoms (e.g. number of incontinence
episodes (every 24 hours), number of micturitions every 24
hours, pad tests)
5. Socioeconomic measures (e.g. costs of interventions, cost
effectiveness of interventions in terms of incremental cost-
effectiveness ratios (ICERs), costs per quality-adjusted life year
(QALY) or cost-benefit ratios)
6. Adverse effects (e.g. skin or tissue damage, pain or
discomfort, vascular, visceral or nerve injury, voiding
dysfunction)
Tertiary outcomes
Wewill extract data related to the following assessments as indirect
measures of the physiological effect of treatment:
1. Clinicians’ observations e.g. objectively-measured cure or
improvement, incontinence (such as observation of leakage,
leakage observed at urodynamics study)
2. Pelvic floor muscle strength or ability to contract the pelvic
floor muscles, or both
3. Any other outcomes judged important when performing
the review.
Main outcomes for ’Summary of findings’ table
Wewill apply the principles of the GRADE system (Guyatt 2008)
to assess the quality of the body of evidence. This approach uses
four categories (very low, low, moderate and high) to rate the
quality of evidence available for selected outcomes; for instance
evidence from RCTs is initially judged to be high quality but this
can be downgraded if there are other indications of low quality,
such as small sample sizes or high risk of bias.
Wewill include the following outcomes in a ’Summary of findings’
table:
1. Number of women with self-reported continence
2. Number of women with self-reported improvement in SUI
3. QoL measures due to SUI
4. Adverse effects: pain or discomfort due to treatment
5. Cost effectiveness of interventions
Search methods for identification of studies
We will not impose any restrictions, for example language or pub-
lication status, on the searches described below.
Electronic searches
This review will draw on the search strategy developed for the
Cochrane Incontinence Group. We will identify relevant trials
from the Cochrane Incontinence Group Specialised Register. For
more details of the search methods used to build the Specialised
Register please see the Group’s module in the Cochrane Library.
The register contains trials identified from the Cochrane Central
Register of Controlled Trials (CENTRAL), MEDLINE, MED-
LINE In-Process, ClinicalTrials.gov, WHO ICTRP and hand-
searching of journals and conference proceedings. Most of the tri-
als in the Cochrane Incontinence Group Specialised Register are
also contained in CENTRAL.
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The terms that we will use to search the Incontinence Group
Specialised Register are given in Appendix 1.
Cost-effectiveness searches
We will also undertake separate searches to identify studies ex-
amining the cost effectiveness of ES for SUI. Databases to be
searched will include: Health Management Information Con-
sortium (HMIC), Cost-Effectiveness Analysis Registry (CEA
Registry) and Research Papers in Economics (RePEc).
Searching other resources
We will check the reference lists of the identified relevant studies
for additional citations. We will consult with clinical specialists
and will contact the authors of included trials where appropriate,
to obtain unpublished data or to seek clarification on ambiguous
data in published trial reports.
Data collection and analysis
Selection of studies
Two authors will independently screen the trials identified by the
literature search, resolving any disagreements by discussion or by
referring to a third party.
Data extraction and management
Two authors will extract data independently, resolving any dis-
agreements by discussion or by referring to a third party. We will
use a standard data extraction form to extract data on study char-
acteristics (design, methods of randomisation), participants, in-
terventions and outcomes.
Assessment of risk of bias in included studies
We will assess risks of bias with the Cochrane ’Risk of bias’ tool
(Higgins 2011), which addresses the following kinds of bias:
• Selection bias (randomisation and allocation concealment)
• Performance bias (blinding of participants, caregivers)
• Detection bias (blinding of outcome assessors)
• Attrition bias (incomplete outcome data or differential
withdrawal)
• Reporting bias (selective reporting of outcomes)
Two authors will independently carry out ’Risk of bias’ assessment
and will resolve any disagreements by consulting a third author.
Measures of treatment effect
For dichotomous data, we will calculate the risk ratio (RR) with a
95%confidence interval (CI). For continuous data, wewill present
the mean difference (MD) with a 95% CI. We will calculate the
standardized mean difference (SMD) to combine trials that mea-
sure the same outcome but with different methods.
Unit of analysis issues
We will analyse studies with non-standard designs, such as cross-
over trials and cluster-randomised trials, as described in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). We will analyse studies with multiple treatment groups by
treating each pair of arms as a separate comparison, as appropriate.
Where data from randomised cross-over trials are incomplete we
will consider including data from the first period of randomisation
only.
The unit of analysis will be each participant recruited into the
trials.
Dealing with missing data
We will analyse data on an intention-to-treat (ITT) basis as far as
possible, whereby all participants must be analysed according to
the groups to which theywere randomised. Where participants are
excluded after allocation or withdraw from the trial, we will report
any details provided in full. Where data from randomised cross-
over trials are incomplete we will consider including data from the
first period of randomisation only.
Where trials reportmean values without standard deviations (SDs)
but with P values or 95% CIs, we will use the Review Manager
5 calculator to estimate the SD. Where trials report mean values
only, we will assume the outcome to have a SD equal to the highest
SD from the other trials within the same analysis.
We will make all reasonable attempts to contact authors for clari-
fication of missing data.
Assessment of heterogeneity
We will assess clinical heterogeneity by examination of the trial
methods, and test for statistical heterogeneity between trial results
using the Chi2 test and the I2 statistic, with the following cut-offs
(Higgins 2011):
• < 30% heterogeneity may not be important
• 30% to 50% may represent moderate heterogeneity
• > 50% may represent substantial heterogeneity
Assessment of reporting biases
We will assess the likelihood of potential publication bias using
funnel plots, provided that we identify 10 or more eligible trials
contributing to an outcome.
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Data synthesis
We will use the fixed-effect model to analyse data. If we identify
significant heterogeneity (for example I2 higher than 50%), we
will compute pooled estimates of the treatment effect for each
outcome under a random-effects model.
Subgroup analysis and investigation of heterogeneity
If data permit, we will carry out the following subgroup analyses:
• Population: trials with participants with SUI only versus
participants with MUI
• Different approaches to electrode placement
(transcutaneous (e.g. perineal skin, sacral), versus vaginal or
anorectal)
Where we find substantial heterogeneity (I2 > 50%), we will in-
vestigate the possible causes and carry out subgroup analyses as
appropriate.
Sensitivity analysis
If data permit, we will perform sensitivity analysis comparing trials
at low risk of selection bias to those at high risk of selection bias,
which will explore the robustness of the results.
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A P P E N D I C E S
Appendix 1. Search strategy
Cochrane Incontinence Group Specialised Register
The terms that will be used to search the Incontinence Group Specialised Register are given below:
(({DESIGN.CCT*} OR {DESIGN.RCT*}) AND {INTVENT.PHYS.ELECTSTIM*} AND {TOPIC.URINE.INCON*})
(All searches will be of the keyword field of Reference Manager 2012).
Cost-effectiveness searches
Embase, MEDLINE In-Process & Other Non-Indexed Citations, MEDLINE
Ovid multifile search
1. exp “costs and cost analysis”/
2. economics/
3. exp economics,hospital/
4. exp economics,medical/
5. economics,pharmaceutical/
6. exp budgets/
7. exp models, economic/
8. exp decision theory/
9. ec.fs.
10. monte carlo method/
11. markov chains/
12. exp health status indicators/
13. cost$.ti.
14. (cost$ adj2 (effective$ or utilit$ or benefit$ or minimis$)).ab.
15. economic$ model$.tw.
16. (economic$ or pharmacoeconomic$ or pharmaco-economic$).tw.
17. (price$ or pricing).tw.
18. (financial or finance or finances or financed).tw.
19. ((value adj2 money) or monetary).tw.
20. markov$.tw.
21. monte carlo.tw.
22. (decision$ adj2 (tree? or analy$ or model$)).tw.
23. (standard adj1 gamble).tw.
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24. trade off.tw.
25. or/1-22
26. electrostimulation/
27. Electric Stimulation/
28. neuromodulation/
29. (electrical stimulation or neuromodulation or ((percutaneous or transcutaneous) adj4 stimulation)).tw.
30. or/26-29
31. urine incontinence/ or mixed incontinence/ or stress incontinence/
32. urinary incontinence/ or urinary incontinence, stress/
33. ((stress or urinary) adj3 incontinence).tw.
34. or/31-33
35. 25 and 30 and 34
36. 35 not (letter or comment$ or editorial or note).pt.
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